SynphaBase AG is a Swiss-based custom research and development organization (CRDO) specializing in medicinal chemistry, process R&D, and glycoscience, including high-purity carbohydrate synthesis. Established in 2000 and servicing pharma, biotech, fine chemicals, and academic sectors, the company offers integrated support from early-stage route scouting to GMP-grade manufacturing in partnership with CMOs. With over 2,000 completed projects (from milligram to multi‑kilogram, GMP & non‑GMP) as of ~2024, SynphaBase emphasizes process optimization, reproducibility, and structural precision tailored to complex molecule types. Innovation focuses heavily on oligosaccharides and carbohydrate-conjugates. Synphabase operate under an ISO9001:2015-certified quality management system and are authorized by Swissmedic to support GMP-compliant processes through qualified contract manufacturing partners (CMOs).
Looking for a particular SynphaBase AG employee's phone or email?
The SynphaBase AG annual revenue was $5.6 million in 2026.
Arthur Bodenmueller is the CEO of SynphaBase AG.
8 people are employed at SynphaBase AG.
SynphaBase AG is based in Pratteln, Basel-landschaft.
The NAICS codes for SynphaBase AG are [32, 325, 32541, 3254].
The SIC codes for SynphaBase AG are [28, 283].